Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Augmenting Dual Energy CT for Novel Contrast Agents

    SBC: NEXTRAST, INC            Topic: 300

    Project SummaryAbstract Our long term goal is to revolutionize the effectiveness of CT imaging for millions of Americans across a broad range of abdominal diseaseDual energy CTDECTprovides powerful clinical diagnostic potential but remains heavily underutilized despite wide scanner availabilityDECT allows materials to be differentiated based on their relative X ray attenuation at low versus high e ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. BlueBox: A Complete Code Blue Data Recorder, Phase II

    SBC: NeoVative, Inc.            Topic: 400

    Code blueis the signal used in hospitals to call for an immediate cardiopulmonary resuscitationCPRfollowing a cardiac or respiratory arrestReviewing the performance of thecode blue teamis a cornerstone for improving outcomesThe current standard of using handwritten records on a papercode sheetdoes not allow measurement of key quality indicators and is subject to human errorIn the Phase I STTR proj ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Compact Laser Drivers for Photoconductive Semicond

    SBC: SCIENTIFIC APPLICATIONS & RESEARCH ASSOCIATES, INC.            Topic: DTRA16A004

    For effective protection against radiated threats, it is important to understand not only the physics of the threats, but also to quantify the effects they have on mission-critical electrical systems. Radiated vulnerability and susceptibility testing requires delivery of high peak power and peak electric fields to distant targets. The most practical solution to simulate such environments on large ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  4. Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers

    SBC: Protein Metrics Inc.            Topic: 400

    Project SummaryGlycosylation is one of the most prevalent and important post translational modifications of proteinsyet it is also one of the most difficult to studyNo single method nor analytical platform can give complete information about the glycosylation in a protein sampleand the analytical methods in current use include both ESI and MALDI single and tandem mass spectrometryat least four typ ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Deriving Bone Density from Thoracic CT Scans, STTR Phase II

    SBC: BDI, Inc.            Topic: NIAMS

    ABSTRACT Osteoporosis is a major cause of disability and morbidity in our populationAs many asmillion Americans have osteoporosis andmillion more have osteopeniaHoweverbone mineral densityBMDassessment does not occur in many Americans when indicated and measure currently requires a separate referral and separate imaging scan to obtain BMDThe result is that onlyof Americans who are at risk of suffe ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users

    SBC: AUTOMATE SCIENTIFIC, INC.            Topic: NIDA

    Abstract E cigarettesE cigsare increasingly popular worldwidein particularamong youthsE cigs may contribute to nicotine addiction and are unlikely to discourage conventional cigarette smokingMainstream and second hand E cig aerosols containin addition to nicotinedetectable levels of toxins including carcinogens and heavy metals such as formaldehydebenzenenitrosaminescadmium and leadTherefore healt ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    TypeDiabetesT Daffects an ever growing populationWhile this disease typically has been associated with juvenilesthe disease in adult populations is rapidly increasingThe defining clinical component is insulin losswhich occurs because of sustained inflammation in the isletsAt present there is no means to prevent or reverse insulin lossA major inflammatory pathway in T D that contributes to insulin ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of breakthrough intra-operative detector and imaging system for parat

    SBC: Anasys Instruments Corp.            Topic: 102

    DESCRIPTION provided by applicant There are parathyroid glands in the neck and they are responsible for the production of parathyroid hormone which maintains calcium homeostasis throughout the body They are difficult to identify relative to the other tissues in the neck such s lymph nodes fat thyroid etc This has resulted in the incidence of accidental parathyroid removal ranging from ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Pirenzepine for CIPN

    SBC: WinSanTor, Inc.            Topic: NCI

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government